Xilio Therapeutics (XLO) Q1 2025 earnings summary

Executive summary

• Entered a major collaboration, license, and option agreement with AbbVie for up to four tumor-activated immunotherapy programs, including a $42M upfront payment and $10M equity investment, with up to $2.1B in potential milestones and royalties.

• Reported $2.9M in collaboration and license revenue for Q1 2025, driven by new AbbVie and Gilead agreements; no product sales revenue.

• Net loss for Q1 2025 was $13.3M, an improvement from $17.2M net loss in Q1 2024, reflecting lower R&D expenses and new collaboration revenue.

• Cash and cash equivalents were $89.1M as of March 31, 2025, expected to fund operations into Q1 2026, but not for 12 months from report issuance, raising substantial doubt about going concern.

• Presented initial Phase 2 data for vilastobart in combination with atezolizumab, showing a 27% objective response rate in late-line MSS CRC patients without liver metastases and a favorable safety profile.

Financial highlights

• Q1 2025 revenue: $2.9M (vs. $0 in Q1 2024), all from collaboration and license agreements.

• Net loss: $13.3M in Q1 2025 (vs. $17.2M in Q1 2024); net loss per share improved to $(0.18) from $(0.62) year-over-year.

• R&D expenses decreased to $8.3M (from $10.4M), mainly due to portfolio reprioritization and lower headcount.

• G&A expenses increased to $8.5M (from $6.1M), driven by higher personnel and professional fees.

• Cash provided by operating activities was $29.0M in Q1 2025, reflecting upfront payments from AbbVie.

Outlook and guidance

• Cash runway expected into Q1 2026, but not sufficient for 12 months from financial statement issuance; additional capital needed to continue operations.

• Management is pursuing additional equity, debt, or partnership funding; failure to secure capital may require cost reductions or program delays.

• Plans to report updated Phase 2 data for vilastobart at ASCO 2025 and nominate development candidates for multiple T cell engager programs in 2025 and 2026.

• No product sales expected for several years; future revenue to depend on milestone payments and royalties from AbbVie and Gilead collaborations.